Andson Biotech was created to build, from the ground up, bioanalytical platforms to fill the void of existing sensor-technologies for advanced biomanufacturing. Our goal is to accelerate the development and improve the production of advanced therapies such that they can reach a broad patient population. Our technologies were developed to analyze three key aspects of any biomanufacturing process which relies on living cells 1) the secretome, 2) the intracellular content and 3) the cell-surface profile.
The secretome analysis system (SecrAS) was first developed with support from the National Science Foundation (NSF) Engineering Research Center (ERC) for Cell Manufacturing Technologies (CMaT) during the PhD studies of Mason Chilmonczyk (co-founder) while working under the guidance of Andrei Fedorov (co-founder). With the input of both CMaT and the greater advanced therapy ecosystem, including the Marcus Center for Therapeutic Cell Characterization and Manufacturing (MC3M), this technology was designed from scratch to meet the needs of modern cell and gene workflows. The intracellular analysis system (IntAS) was developed after the SecrAS to capture the biochemical state within a cell, and triple-shot analysis system (TriAS) represents the final frontier of complete cell state analysis including cell-surface profiling. Together, our process analytical technologies will provide innovative methodologies for understanding bioproduction from lab-to-market.